Leadership and Board of Directors
Jeffrey L. Goldberg, MD, PhD
Co-founder and Director, Board of Managers
Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology and Director of the Byers Eye Institute at Stanford University. His focus is on regenerative medicine in eye and vision research, and on developing novel molecular, stem cell, and nanotherapeutics approaches for eye repair. Jeff completed his clinical training in ophthalmology and glaucoma at the Bascom Palmer Eye Institute. He received his BS magna cum laude from Yale, and his MD and PhD from Stanford.
Roger A. Goldberg, MD, MBA
Co-founder and Chief Medical Advisor
Dr. Roger Goldberg is a vitreoretinal surgeon with expertise in clinical trial design and implementation. He did his clinical training in ophthalmology at the Bascom Palmer Eye Institute and vitreoretinal fellowship at Tufts University. Previously, Roger worked for McKinsey & Co. in healthcare consulting. He received his BA, MD, and MBA from Yale.
Noelia J. Kunzevitzky, PhD
Chief Operating Officer
Dr. Kunzevitzky focuses on innovation and regenerative medicine. An executive with over 20 years of experience in ophthalmology, she leads teams in pre-clinical development, cell manufacturing, regulatory project management, and clinical trials. Noelia obtained her BS at Universidad Nacional de Cordoba in Argentina and completed her PhD in cell biology and postdoctoral training in bioinformatics at the University of Miami.
Cyril Allouche, MBA
Chief Financial Advisor
Mr. Allouche brings over 25 years of experience in finance leadership in both public and pre-IPO companies, including biopharmaceutical, medical devices, and diagnostics. He most recently served as CFO at Avellino Lab, LensGen, Dermavant Sciences and held finance leadership roles at Revance Therapeutics and CareDx. He also spent over a decade at PricewaterhouseCoopers in Audit and Transaction services. Cyril is a California Certified Public Accountant and holds a Master of Accountancy from University of Georgia and a Master of Business Administration from University of Paris-East.
James V. Mazzo
Board of Directors
James V. (Jim) Mazzo is the Executive Chair of Neurotech, a private clinical-stage biotech company developing transformative therapies for chronic eye diseases. One of the ophthalmic industry's most respected business leaders with more than 40 years of proven experience in the medical device space, Mr. Mazzo is internationally renowned for building and running world-class organizations. He has held several leadership positions, including CEO of Allergan's North American and European eye care organizations; chairman, president and CEO of Advanced Medical Optics (AMO); EVP of Abbott's global ophthalmology business; executive chair and CEO of AcuFocus; and global president of ophthalmic devices for Carl Zeiss Meditec.
James W. Donaghy, MBA
Board of Directors
Mr. Donaghy has over thirty years experience in private equity investing. He serves as the President and is on the Board of Holding Capital Groups' principal investment entities. He also serves (or has served) on the Boards of portfolio companies in precision injection molding, building materials, men's apparel, wire and cable, concrete products, and metal and rubber manufacturing industries amongst others. Mr. Donaghy holds a BS in Business Administration from the University of Nebraska and an MBA from Pace University.
Cornea Advisory Board
Victor Perez, MD
Professor of Ophthalmology and Cornea Research Program Director, Bascom Palmer Eye Institute